

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

1497 Selected Articles from This Issue

MCT FIRST DISCLOSURES

1499 **TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations**

Brion W. Murray, Dayong Zhai, Wei Deng, Xin Zhang, Jane Ung, Vivian Nguyen, Han Zhang, Maria Barrera, Ana Parra, Jessica Cowell, Dong J. Lee, Herve Aloysius, and Evan Rogers

1508 **SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors**

Alba Gonzalez-Junca, Frances D. Liu, Archana S. Nagaraja, Alyssa Mullenix, Chen-Ting Lee, Russell M. Gordley, Daniel O. Frimannsson, Ori Maller, Brian S. Garrison, Dharini Iyer, Anissa Benabbas, Tiffany A. Truong, Allison Quach, Mengxi Tian, Rowena Martinez, Rishi Savur, Alyssa Perry-McNamara, Denny Nguyen, Niran Almudhfar, Carmina Blanco, Christina Huynh, Asish Nand, Yu-An E. Lay, Ashita Magal, Sravani Mangalampalli, Philip J. Lee, Timothy K. Lu, and Gary Lee

REVIEWS

1521 **Current Development of Glioblastoma Therapeutic Agents**

Zilai Wang, Norton P. Peet, Pin Zhang, Yuwei Jiang, and Lijun Rong

1533 **T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy**

Zhijian Duan and Mitchell Ho

1542 **Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance**

Nidhi Goel, McKenzie E. Foxall, Carly Bess Scalise, Jaelyn A. Wall, and Rebecca C. Arend

SMALL MOLECULE THERAPEUTICS

1550 **Suppression of Extracellular Vesicle VEGF-C-mediated Lymphangiogenesis and Pancreatic Cancer Early Dissemination By a Selective HDAC1/2 Inhibitor**

Chu-An Wang, Chien-Feng Li, Rho-Chi Huang, Yo-Hua Li, Jing-Ping Liou, and Shaw-Jenq Tsai

1561 **VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases**

Thomas L. Ekstrom, Nicholas M. Pathoulas, Amelia M. Huehls, Arun Kanakkanthara, and Larry M. Karnitz

1572 **ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer**

Isacco Ferrarini, Anna Louie, Lanlan Zhou, and Wafik S. El-Deiry

1584 **Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma**

Matthias A. Karajannis, Audrey Mauguen, Ekrem Maloku, Qingwen Xu, Erin M. Dunbar, Scott R. Plotkin, Anna Yaffee, Shiyang Wang, J. Thomas Roland, Chandranath Sen, Dimitris G. Placantonakis, John G. Golfinos, Jeffrey C. Allen, Nicholas A. Vitanza, Luis A. Chiriboga, Robert J. Schneider, Jingjing Deng, Thomas A. Neubert, Judith D. Goldberg, David Zagzag, Filippo G. Giaccotti, and Jaishri O. Blakeley

1592 **Targeting Tfr1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV⁺ Human Primary B-cells**

Laura E. Martinez, Tracy R. Daniels-Wells, Yu Guo, Larry I. Magpantay, Pierre V. Candelaria, Manuel L. Penichet, Otoniel Martinez-Maza, and Marta Epeldegui

1603 **β -Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAF^{V600E}-Driven Thyroid Cancer Animal Model**

Minjing Zou, Huda A. BinEssa, Yousif H. Al-Malki, Suhad Al-Yahya, Monther Al-Alwan, Ibrahim Al-Jammaz, Khalid S.A. Khabar, Falah Almohanna, Abdullah M. Assiri, Brian F. Meyer, Ali S. Alzahrani, Futwan A. Al-Mohanna, and Yufei Shi

TABLE OF CONTENTS

1614 Radiopotential Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development

Sonja J. Gill, Paul W.G. Wijnhoven, Jacqueline H.L. Folk, Rebecca L. Lloyd, Jonathan Cairns, Joshua Armenia, Jenni Nikkilä, Alan Lau, Christopher J. Bakkenist, Susan M. Galbraith, Conchita Vens, and Mark J. O'Connor

1627 Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer

Nyree Crawford, Katie J. Stott, Tamas Sessler, Christopher McCann, William McDaid, Andrea Lees, Cheryl Latimer, Jennifer P. Fox, Joanne M. Munck, Tomoko Smyth, Alpesh Shah, Vanessa Martins, Mark Lawler, Philip D. Dunne, Emma M. Kerr, Simon S. McDade, Vicky M. Coyle, and Daniel B. Longley

1640 C/EBP β /AEP Signaling Regulates the Oxidative Stress in Malignant Cancers, Stimulating the Metastasis

Kecheng Lei, Seong Su Kang, Eun Hee Ahn, Chun Chen, Jianming Liao, Xia Liu, Hua Li, Laura E. Edgington-Mitchell, Lingjing Jin, and Keqiang Ye

1653 SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer

Hirohisa Kano, Eiki Ichihara, Hiromi Watanabe, Kazuya Nishii, Chihiro Ando, Takamasa Nakasuka, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Kammei Rai, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, and Katsuyuki Kiura

1663 DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models

Yanyan Jiang, Elaine Willmore, Stephen R. Wedge, and Anderson J. Ryan

1672 The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells

Hong Shik Yun, Jennifer Lee, Whoon Jong Kil, Tamalee R. Kramp, Philip J. Tofilon, and Kevin Camphausen

1680 PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer

Cheng Wu, Shan Peng, Patrick G. Pilié, Chuandong Geng, Sanghee Park, Ganiraju C. Manyam, Yungang Lu, Guang Yang, Zhe Tang, Shakuntala Kondraganti, Daoqi Wang, Courtney W. Hudgens, Debora A. Ledesma, Mario L. Marques-Piubelli, Carlos A. Torres-Cabala, Jonathan L. Curry, Patricia Troncoso, Paul G. Corn, Bradley M. Broom, and Timothy C. Thompson

1692 A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy

Di Zhang, Zhilin Hou, Kelly E. Aldrich, Lizbeth Lockwood, Aaron L. Odom, and Karen T. Liby

LARGE MOLECULE THERAPEUTICS

1702 Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells

Wen-Hsin Sandy Lee, Zhiyong Ye, Alice M.S. Cheung, Y.P. Sharon Goh, Hsueh Ling Janice Oh, Ravisankar Rajarethinam, Siok Ping Yeo, Mun Kuen Soh, Esther Hian Li Chan, Lip Kun Tan, Soo-Yong Tan, Charles Chuah, Wee Joo Chng, John E. Connolly, and Cheng-I Wang

1713 Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma

Keiichiro Yokota, Satoshi Serada, Shigehiro Tsujii, Keisuke Toya, Tsuyoshi Takahashi, Takashi Matsunaga, Minoru Fujimoto, Sunao Uemura, Tsutomu Namikawa, Ichiro Murakami, Shogo Kobayashi, Hidetoshi Eguchi, Yuichiro Doki, Kazuhiro Hanazaki, and Tetsuji Naka

1723 Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity

James Harper, Shannon Burke, Jon Travers, Nicola Rath, Andrew Leinster, Christel Navarro, Ruth Franks, Rebecca Leyland, Kathy Mulgrew, Kelly McGlinchey, Lee Brown, Simon J. Dovedi, Jens-Oliver Koopmann, Nicholas M. Durham, Xing Cheng, Hong Jin, Jim Eyles, Robert W. Wilkinson, and Danielle Carroll

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1735 Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study

Hong Zheng, Yunong Gao, Hongyan Guo, Li Li, Qingshui Li, Heng Cui, An Lin, Lixin Sun, Yuanjing Hu, Shan Kang, Wei Duan, Lingya Pan, Shuzhen Wang, Yingjie Yang, Yunxia Li, Weimin Kong, Yang Xiang, Xiaofei Tian, Bin Ling, Chunfang Ha, and Wenpei Bai

MODELS AND TECHNOLOGIES

1743 Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction


David E. Durrant, Emily A. Smith, Ekaterina I. Goncharova, Nirmala Sharma, Patrick A. Alexander, Andrew G. Stephen, Curtis J. Henrich, and Deborah K. Morrison

TABLE OF CONTENTS

ABOUT THE COVER

SENTI-101 is a novel allogeneic cell therapy for the treatment of peritoneal carcinomatosis, including advanced ovarian cancer. Genetically modified mesenchymal stem cells deliver IL-12 and IL-21 to peritoneal tumors, attracting and activating immune cells. Read the full article on page 1508.

doi: 10.1158/1535-7163.MCT-20-9-CVR



Molecular Cancer Therapeutics

20 (9)

Mol Cancer Ther 2021;20:1497-1754.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/20/9>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/9>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.